QIAGEN N.V.: QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson's Disease Drug
Initial development and validation of clinical trial assay Next-generation sequencing (NGS) based assay targeting LRRK2 from blood samples Collaboration expands QIAGEN's NGS testing